← Back to Clinical Trials
Recruiting NCT05837325

NCT05837325 Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst?

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05837325
Status Recruiting
Phase
Sponsor ART Fertility Clinics LLC
Condition Infertility, Female
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2023-05-23
Primary Completion 2026-12-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 40 Years
Study Type OBSERVATIONAL
Interventions
Oocyte Pick Up - Out of StudyDenudation - Out of StudyICSI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2023-05-23 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To investigate, whether on the day of egg retrieval, after ovarian stimulation for ICSI (intracytoplasmic sperm injection), there is a correlation between the intrafollicular AMH (Anti-Müllerian hormone) levels and the ploidy status of the blastocyst.

Eligibility Criteria

Inclusion Criteria: * At least one follicle from each ovary at day of trigger * Age from 18 to 40 years old * Normal menstrual cycle of 25-35 days * Poor, normal and high response will be included * First follicle punctured from each ovary will be consider for inclusion: if the COC (Cumulus Oocyte Complex) is present in clear FF (Follicular fluid), the FF will be collected separately for further analysis and the oocyte included in the study Exclusion Criteria: * Very hematic follicular fluid * If the COC is not found in the follicular fluid * Azoospermia * Known chromosomal abnormalities * Severe OAT (Oligoasthenoteratozoospermia)

Contact & Investigator

Central Contact

Barbara Lawrenz, PhD

✉ barbara.lawrenz@artfertilityclinics.com

📞 0097126528000

Principal Investigator

Laura Melado, PhD

PRINCIPAL INVESTIGATOR

ART Fertility Clinics LLC

Frequently Asked Questions

Who can join the NCT05837325 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Infertility, Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05837325 currently recruiting?

Yes, NCT05837325 is actively recruiting participants. Contact the research team at barbara.lawrenz@artfertilityclinics.com for enrollment information.

Where is the NCT05837325 trial being conducted?

This trial is being conducted at Abu Dhabi, United Arab Emirates.

Who is sponsoring the NCT05837325 clinical trial?

NCT05837325 is sponsored by ART Fertility Clinics LLC. The principal investigator is Laura Melado, PhD at ART Fertility Clinics LLC. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology